Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
Latest Aithority Insights: Detecting, Addressing and Debunking the Hidden AI Biases
“We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics’ Nautilus AI-driven peptide design platform and Orion’s GPCR platform, we aim to reduce the risk, time and cost for drug design.”
The collaboration will combine the capabilities of Peptilogics’ AI platform (Nautilus) with Orion Biotechnology’s proprietary drug discovery platform. The companies will leverage expertise in peptide design and engineering to drive drug discovery against an undrugged peptidergic GPCR linked to highly prevalent, life-threatening diseases.
AI and ML News: AI: Continuing the Chase for Brain-Level Efficiency
Peptilogics’ Nautilus platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom-design therapeutics. Additionally, Peptilogics’ supercomputer accelerates model development, prediction and evaluation of peptide sequences to produce higher quality hits with greater chance of success. Synergistically, Orion Biotechnology’s platform explores receptor-ligand shape space using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced potency and tailored signaling activity. Orion’s platform generates data matrices for AI-assisted lead optimization, offering one of the fastest drug discovery and development solutions to target peptidergic GPCRs.
On the announcement of this collaboration, Dr. Oliver Hartley, VP Drug Discovery at Orion Biotechnology, commented, “We are pleased to be partnering with Peptilogics to push the boundaries of receptor pharmacology and AI computing to accelerate innovation for improved patient outcomes. An AI-driven paradigm shift is happening in drug discovery, and Orion is pleased to be at the forefront of applying AI to the highly valuable space around GPCRs. The ideal fit between Orion’s platform and unique knowledge of receptor-ligand interactions with Peptilogics’ machine learning models will position us to make AI-driven GPCR drug discovery a reality.”
“Using Peptilogics’ Nautilus platform, we combine proprietary deep generative models, predictive models and biophysical simulation to design multiparameter-optimized peptides that have the potential to address historically challenging and novel drug targets. Our AI algorithms enable efficient navigation of the vast peptide design space, allowing us to uncover molecules that may not be discovered through traditional screening,” said Nicholas Nystrom, Ph.D., Chief Technology Officer of Peptilogics. “We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics’ Nautilus™ AI-driven peptide design platform and Orion’s GPCR platform, we aim to reduce the risk, time and cost for drug design.”
AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.